KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702].

M Burotto, Z Zvirbule, A Mochalova, Y Runglodvatana, L Herraez-Baranda, S N Liu, P Chan, E Shearer-Kang, X Liu, N Tosti, J A Zanghi, B Leutgeb, E Felip

Ann Oncol 35(5) 482

PMID38195363
PMCID-
DOI10.1016/j.annonc.2023.12.005
发表日期2024-01-09
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。